{"id":"tp-54446","type":"article-newspaper","title":"Cumberland Pharmaceuticals Posts $2.16 Million Q3 Revenue, $0.07 Loss Per Share From Continuing Operations","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/54446","datePublished":"2026-11-11T20:48:39.000Z","dateModified":"2026-11-11T20:48:39.000Z","language":"en","abstract":"GAAP net income reached $77.8 million, including an $81.1 million gain on disposal of discontinued operations.","section":"Business","references":[]}